BRCA1 and breast carcinoma: In the only, recent pilot study by Berstein et al, the investigators administered a dose of 1.0-1.5 grams/day for 3 months in 6 postmenopausal women with breast cancer, three of whom were BRCA1 carriers and demonstrated safety as well data suggesting the possibility that aromatase complex activation in BRCA1 mutation carriers is combined with increases in both, estrogen metabolism into catecholestrogens and their inactivation by methoxylation, and that MET may affect both of these pathways [43].